Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial.
Published in Journal of clinical oncology : official journal of the American Society of Clinical Oncology • Aug 1, 2001
Authors:,,
S R Bramhall
A Rosemurgy
P D Brown
Abstract
PURPOSE: The prognosis for unresectable pancreatic cancer remains dismal (1-year survival rate, < 10%; 5-year survival rate, < 5%). Recent advances in conventional chemotherapy and novel molecular treatment strategies warrant investigation. This, the largest randomized study in pancreatic cancer per...
Finding related papers...
Discussions
(0)No comments yet
Be the first to share your thoughts!